Breast Surgeons Live
Back to Activities List
Session Title:
Benign Breast Lesions on Core Needle Biopsy: Navigating the Gray Zone
Date & Time:
January 12, 2027, 7:00 PM–7:45 PM ET
Length:
45 Minutes
CME Deadline:
January 12, 2027
This activity is open to members only:
Log InTarget Audience:
Surgeons and other healthcare providers with a special interest in the treatment of breast disease.
Objectives:
At the end of this activity, participants will be able to:
- Identify benign breast lesions from core needle biopsies that may require surgical excision and others that may be reasonably observed.
- Implement shared decision-making discussions with patients regarding surgical vs surveillance strategies for patients with benign breast biopsies.
Description:
The management of benign breast lesions remains one of the most nuanced areas of breast surgery. As our understanding of upgrade rates, radiologic-pathologic concordance, and lesion-specific risk continues to evolve, increasing numbers of patients may be safely managed without surgical excision. This webinar will review contemporary evidence for the management of benign breast lesions identified on core needle biopsy and discuss practical approaches to individualized decision-making.
Agenda:
Welcome and Introduction
Moderators: J. Jaime Alberty-Oller, MD, FACS & Jennifer K. Plichta, MD, MS, FACS
When Observation Is Appropriate: Contemporary Management of Benign Breast Lesions
Faina Nakhlis, MD
When Surgery Still Matters: Selecting Patients for Excision
Suzanne Coopey, MD
Faculty:
Moderator—J. Jaime Alberty-Oller, MD, FACS
Kings County Hospital/NYC Health and Hospitals System
Brooklyn, NY
Moderator—Jennifer K. Plichta, MD, MS, FACS
Duke University
Durham, NC
Faina Nakhlis, MD, FACS
Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center
Associate Director, Inflammatory Breast Cancer Program
Associate Professor of Surgery, Harvard Medical School
Boston, MA
Associate Director, Inflammatory Breast Cancer Program
Associate Professor of Surgery, Harvard Medical School
Boston, MA
Suzanne B. Coopey, MD, FACS
Director of Breast Surgery, Allegheny Health Network
Chair, Breast Cancer Program, AHN Cancer Institute
Associate Professor of Surgery, Drexel University College of Medicine
Allegheny Health Network
Pittsburgh, PA
Chair, Breast Cancer Program, AHN Cancer Institute
Associate Professor of Surgery, Drexel University College of Medicine
Allegheny Health Network
Pittsburgh, PA
References:
- Elfgen C, Leo C, Kubik-Huch RA, Muenst S, Schmidt N, Quinn C, McNally S, van Diest PJ, Mann RM, Bago-Horvath Z, Bernathova M, Regitnig P, Fuchsjäger M, Schwegler-Guggemos D, Maranta M, Zehbe S, Tausch C, Güth U, Fallenberg EM, Schrading S, Kothari A, Sonnenschein M, Kampmann G, Kulka J, Tille JC, Körner M, Decker T, Lax SF, Daniaux M, Bjelic-Radisic V, Kacerovsky-Strobl S, Condorelli R, Gnant M, Varga Z. Third International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Virchows Arch. 2023 Jul;483(1):5-20. doi: 10.1007/s00428-023-03566-x. Epub 2023 Jun 17. PMID: 37330436; PMCID: PMC10326140.
- Harbhajanka A, Gilmore HL, Calhoun BC. High-risk and selected benign breast lesions diagnosed on core needle biopsy: Evidence for and against immediate surgical excision. Mod Pathol. 2022 Nov;35(11):1500-1508. doi: 10.1038/s41379-022-01092-w. Epub 2022 Jun 2. PMID: 35654997.
- Shehata MN, Rahbar H, Flanagan MR, Kilgore MR, Lee CI, Ryser MD, Lowry KP. Risk for Upgrade to Malignancy After Breast Core Needle Biopsy Diagnosis of Lobular Neoplasia: A Systematic Review and Meta-Analysis. J Am Coll Radiol. 2020 Oct;17(10):1207-1219. doi: 10.1016/j.jacr.2020.07.036. Epub 2020 Aug 27. PMID: 32861602.
- Rubio IT, Wyld L, Marotti L, Athanasiou A, Regitnig P, Catanuto G, Schoones JW, Zambon M, Camps J, Santini D, Dietz J, Sardanelli F, Varga Z, Smidt M, Sharma N, Shaaban AM, Gilbert F. European guidelines for the diagnosis, treatment and follow-up of breast lesions with uncertain malignant potential (B3 lesions) developed jointly by EUSOMA, EUSOBI, ESP (BWG) and ESSO. Eur J Surg Oncol. 2024 Jan;50(1):107292. doi: 10.1016/j.ejso.2023.107292. Epub 2023 Nov 27. Erratum in: Eur J Surg Oncol. 2024 Mar;50(3):107943. doi: 10.1016/j.ejso.2023.107943. PMID: 38061151.
- Laws A, Katlin F, Nakhlis F, Chikarmane SA, Schnitt SJ, King TA. Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision. Ann Surg Oncol. 2022 Mar;29(3):1660-1667. doi: 10.1245/s10434-021-10827-z. Epub 2021 Sep 23. PMID: 34554341.
- Nakhlis F, Gilmore L, Gelman R, Bedrosian I, Ludwig K, Hwang ES, Willey S, Hudis C, Iglehart JD, Lawler E, Ryabin NY, Golshan M, Schnitt SJ, King TA. Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020). Ann Surg Oncol. 2016 Mar;23(3):722-8. doi: 10.1245/s10434-015-4922-4. Epub 2015 Nov 5. PMID: 26542585; PMCID: PMC4984674.
- Nakhlis F, Baker GM, Pilewskie M, Gelman R, Calvillo KZ, Ludwig K, McAuliffe PF, Willey S, Rosenberger LH, Parker C, Gallagher K, Jacobs L, Feldman S, Lange P, DeSantis SD, Schnitt SJ, King TA. The Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In Situ in Patients with Intraductal Papilloma without Atypia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 034). Ann Surg Oncol. 2021 May;28(5):2573-2578. doi: 10.1245/s10434-020-09215-w. Epub 2020 Oct 12. PMID: 33047246.
Disclosures:
coming soon
